The IGF-1R inhibitor BMS-754807, mTOR inhibitor AZD8055, mitosis inhibitor paclitaxel, PI3K/mTOR inhibitor PF-04691502, EZH2 inhibitor GSK343 and VEGFR inhibitor tivozanib showed moderate selectivity to CP CML in our drug testing panel (see Supplementary Figures 3 and 4). The gene discussed is MTOR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.